The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance +/- SD after 6-month protocol: placebo 355 +/- 82 m, sildenafil 324 +/- 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 +/- 1.6, sildenafil 4.1 +/- 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pamrevlumab which is a monoclonal antibody that is directed against connective tissue growth factor appeared to attenuate the progression of IPF.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [69]
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Redelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029 · cited 2×
“No such change occurred, indicating the absence of a drug effect exceeding this distance; 54 m is sometimes considered a ‘‘clinically important’’ change in 6-MWT distance in patients with chronic obstructive pulmonary disease [10].”
BackgroundEchocardiographic Assessment of Pulmonary Hypertension in Patients with Advanced Lung Disease
Arcasoy, S. M., Christie, J. D., Ferrari, V. A., Sutton, M. S. J., Zisman, D. A., Blumenthal, N. P., Pochettino, A., & Kotloff, R. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1130oc · Cited by 906 · cited 1×
“Echocardiographic estimates of pulmonary pressure may not accurately reflect pressures measured by catheterization in the setting of interstitial lung disease [16].”
BackgroundPrevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879 · cited 1×
“The echocardiographic pressure estimates (Table 4) and NT-pro BNP data cited earlier demonstrate that this cohort was at risk for pulmonary hypertension, consistent with the literature [1, 12, 13].”
ResultSildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769 · cited 2×
“patients with severe pulmonary fibrosis and pulmonary hypertension associated with disorders of the respiratory system (mean pulmonary arterial pressure 42 mmHg) [5].”
BackgroundResultGuidelines for the six-minute walk test
Ats, S. (2002) · Medical Entomology and Zoology · Cited by 651
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Shorr, A. F., Wainright, J. L., Cors, C. S., Lettieri, C. J., & Nathan, S. D. (2007) · European Respiratory Journal · doi:10.1183/09031936.00107206 · Cited by 377
Ghofrani, H. A., Reichenberger, F., Kohstall, M. G., Mrosek, E. H., Seeger, T., Olschewski, H., Seeger, W., & Grimminger, F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-3-200408030-00005 · Cited by 309 · cited 1×
“However, in contrast to its salutary effects at altitude [15], sildenafil did not increase the exercise capacity of patients with IPF in this trial.”
Background
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
King, C. S., & Nathan, S. D. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30222-3 · Cited by 186
Phosphodiesterase 5 inhibitors for pulmonary hypertension
Barnes, H., Brown, Z., Burns, A., & Williams, T. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012621.pub2 · Cited by 196
A review of current and novel therapies for idiopathic pulmonary fibrosis.
Rafii, R., Juarez, M. M., Albertson, T. E., & Chan, A. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.12.07 · Cited by 173
“There was unfortunately no significant improvement in 6MWD distance or dyspnea score in the sildenafil treatment group (65).”
Background
Metadata
- Authors
- Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O.
- Affiliations
- University of Miami (US)
- Miami VA Healthcare System (US)
- University of Kent (GB)
- Corresponding author
- Jackson, Robert M.
- Venue
- Lung
- Published
- 2009-12-12
- Volume
- 188
- Issue
- 2
- Pages
- 115-123
- ISSN
- 0341-2040 (ISSN-L)
- 1432-1750
- OpenAlex
- W2029732141
- Cited by
- 92
- References
- 18
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 10 · 2015: 4 · 2014: 7 · 2013: 5 · 2012: 5
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Lung (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer UK
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, sildenafil, exercise tolerance, 6-minute walk test, dyspnea, Borg scale, lung function, phosphodiesterase-5 inhibitors
- MeSH terms
- Sildenafil Citrate, Aged, Aged, 80 and over, Double-Blind Method, Dyspnea, Exercise Test, Female, Humans, Male, Middle Aged, Phosphodiesterase Inhibitors, Pilot Projects, Piperazines, Pulmonary Diffusing Capacity, Purines, Sulfones, Time Factors, Vasodilator Agents, Vital Capacity, Treatment Outcome, Exercise Tolerance, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1007/s00408-009-9209-8
- The paper
- Jackson, R. M., Glassberg, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Gómez-Marín, O. (2010). Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. Lung. https://doi.org/10.1007/s00408-009-9209-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.